E
Sell
11/14/2024Downgrade
ZYUS Life Sciences Corporation (ZLSCF) was downgraded to E+ from D- on 11/14/2024 due to a substantial decline in the growth index, total return index and solvency index. The quick ratio declined from 0.26 to 0.13, EBIT declined 43.91% from -$2.36M to -$3.4M, and earnings per share declined from -$0.0371 to -$0.0512.
D
Sell
5/2/2024Upgraded
ZYUS Life Sciences Corporation (ZLSCF) was upgraded to D- from E+ on 5/2/2024 due to a noticeable increase in the total return index and volatility index.
E
Sell
2/27/2024Upgraded
ZYUS Life Sciences Corporation (ZLSCF) was upgraded to E+ from E on 2/27/2024 due to a noticeable increase in the volatility index and total return index.
E
Sell
2/1/2024Upgraded
ZYUS Life Sciences Corporation (ZLSCF) was upgraded to E from E- on 2/1/2024 due to a significant increase in the growth index, total return index and solvency index. Earnings per share increased from -$0.2297 to -$0.0448, total revenue increased 28.8% from $57.3 to $73.8, and EBIT increased 21.74% from -$3.75M to -$2.93M.
E
Sell
11/14/2023None
ZYUS Life Sciences Corporation (ZLSCF) was downgraded to E- from U on 11/14/2023.
